查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198064

產後出血設備市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Postpartum Hemorrhage Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內（2022 年至 2027 年），產後出血設備市場預計將以 5.1% 的複合年增長率增長。

COVID-19 大流行最初對產後出血設備市場產生了重大影響。 美國婦產科學院 2022 年的一份報告發現，與非孕婦相比，有症狀的患有 COVID-19 的孕婦更有可能需要重症監護或需要呼吸機（用於呼吸支持），也更有可能死於疾病。 然而，孕婦患重病或死亡的總體風險很小。 雖然 COVID-19 的爆發對其前身的市場增長產生了負面影響，但妊娠並發症的數量正在增加，推動了對產後出血設備的需求，以治療患者和挽救母親的生命。它正在增加並促進行業的發展。

此外，妊娠並發症發生率的增加是推動產後止血裝置需求的主要因素，有助於市場的增長。 婦產科雜誌上發表的 2021 年公告解釋了懷孕期間貧血的不人道之處。 缺鐵和大量出血是孕期和產後貧血的最常見原因。 懷孕期間對鐵的需求增加，未能維持足夠的鐵水平會對母親和胎兒產生不利影響。 預計這些因素將促進產後止血裝置的採用並促進市場增長。

此外，市場參與者正在製定營銷策略，例如已推出產品的併購。 例如，默克公司計劃在 2021 年剝離 Organon，這將通過促進更安全的分娩來解決孕產婦健康方面未得到滿足的醫療需求，從而實現其致力於增強女性健康的承諾。宣布收購 Aridia Health 代表 Aridia 的技術 Jada System 旨在誘導自然子宮收縮，以防止分娩後出血過多。 美國食品和藥物管理局根據該公司關鍵的 PEARLE IDE 試驗結果，於 2020 年 8 月批准了 Jada System 的 510(k) 許可。 全球健康投資基金和 AXA IM Artz 通過其影響力投資戰略成為 Aridia 的領先機構投資者。 這些基金是社會影響基金，投資於創新技術，這些技術可以產生有吸引力的財務回報，同時有助於解決世界上一些主要的公共衛生問題。 此外，2021 年 9 月，Stryker 宣布收購醫療設備公司 Gauss Surgical，該公司創建了 TritonTM，這是一個人工智能驅動的實時術中出血監測平台。 Triton 通過更早發現出血和更早干預，在產科和外科手術中顯示出優勢。

此外，主要的市場競爭對手正在通過新產品發布和戰略舉措對行業增長產生積極影響。 例如，2022 年 3 月，Baymatob 的可穿戴設備完成增資，推進其救生勞動監測設備。 Baymatob 的可穿戴設備 Oli 使用創新的傳感器技術和 AI 解釋來檢測產後出血開始前分娩過程中的 PPH 滯留情況。

因此，由於上述因素，所研究的市場預計在分析期內會出現增長。 然而，缺乏訓練有素的專業人員正在製約產後出血市場的增長。

產後止血器市場趨勢

預計在預測期內子宮填塞裝置將大幅增長

子宮球囊填塞是一種治療難治性產後出血的非手術療法。 在確認產後出血並進行藥物治療後，它可用於填塞子宮出血而無需手術干預。 充滿液體後，將塌陷的球囊置於子宮內，使其順應宮腔形狀，填塞子宮出血。 導管的中央內腔便於引流，並用於檢測氣囊水平以上發生的出血。 子宮填塞是通過填塞出血子宮表面來控制產後出血的一種安全、簡單、實用的方法。

2021 年在 MDLinx 上發表的一項研究描述了真空引導子宮壓塞裝置的未來進展，該裝置可對子宮施加負壓、收縮出血腔並關閉滲漏血管。 這種低成本、無創的方法在其他治療選擇有限的發展中國家可能很有價值。 因此，子宮球囊填塞帶來的好處可能會增加目標人群對這些產品的採用，最終推動市場的增長。

此外，2021 年，發表在 BMJ Case Reports 上的一篇研究論文發現，避孕套填塞可以顯著降低與產後出血相關的孕產婦發病率和死亡率。 該研究顯示了良好的結果，解釋了避孕套填塞可以節省患者的時間和生命。

如2021年發表在Pubmed Central上的一篇論文，論證了使用Bakriballoon加宮頸粘連術預防和治療妊娠晚期產後出血並發急性主動脈夾層是令人滿意的。你得到了結果。

因此，由於上述因素，預計子宮填塞部分在預測期內將出現顯著的正增長。

預計在預測期內北美將主導產後止血器市場

在預測期內，北美的產後止血裝置市場份額最大。 該地區的出現可歸因於美國和北美其他地區產後出血或分娩的增加。 2020 年英聯邦基金會的一份出版物《美國的孕產婦死亡率和孕產婦護理與其他 10 個發達國家相比》發現，美國的孕產婦死亡率在發達國家中最高。 在美國，以出生後第一年計算，大約三分之一的妊娠相關死亡發生在妊娠期間。 此外，北美產後出血市場受到醫療基礎設施進步和醫療成本上升的推動。 對複雜的產後出血治療的認識不斷提高也推動了市場的發展。

此外，促進產後出血市場增長的其他因素包括主要產品的批准、妊娠並發症上升、死亡率和製造商在國內的存在。 例如：2021 年 9 月，美國食品和藥物管理局批准了 Jada 系統，這是一種用於控制和治療產後異常子宮出血或需要保守治療時出血的醫療器械。 作為 2020 年 8 月 PEARLE IDE 調查（標識符：NCT02883673）的結果，發現 Jada 可有效預防產後出血（主要終點：非手術治療、二次治療，94.3%（n=100/106，P. 001）首次獲批。 由於這些原因，北美地區的市場有望擴大。

產後出血設備市場競爭對手分析

由於多家公司在全球和區域運營，產後出血設備市場是一個分散的市場。 競爭格局包括對幾家具有市場份額的知名國際和本地公司的分析。 包括 Bactiguard、Cook Medical、Utah Medical Products, Inc.、Teleflex Incorporated 和 Organon & Co 等公司。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 妊娠並發症（貧血）的發生率增加，例如胎盤早剝、多胞胎和子宮內翻
    • 增加政府舉措並提高認識
  • 市場製約因素
    • PPH 設備成本高，缺乏訓練有素的專業人員
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按產品類型
    • 非氣動防震服
    • 預填充注射系統
    • 子宮填塞裝置
  • 最終用戶
    • 醫院
    • 診所
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Bactiguard
    • Cook Medical
    • Utah Medical Products, Inc.
    • Teleflex Incorporated
    • Sinapi Biomedical
    • Zoex Niasg
    • 3D Stone Design Inc.
    • Organon & Co.
    • Laborie（Clinical Innovations）
    • Becton, Dickinson and Company
    • Boen Healthcare Co., Ltd

第7章 市場機會與今後動向

簡介目錄
Product Code: 90973

The postpartum hemorrhage devices market is expected to register a CAGR of 5.1% over the forecast period (2022-2027).

The COVID-19 pandemic significantly impacted the market for postpartum hemorrhage devices at the beginning. The American College of Obstetricians and Gynaecologists 2022 reports that pregnant women who have COVID-19 and show symptoms are more likely than nonpregnant women with COVID-19 symptoms to require intensive care, require a ventilator (for breathing support), or die as a result of the illness. Despite this, pregnant women's overall risk of serious disease and death is minimal. The COVID-19 outbreak affected the market's growth adversely in its preliminary phase; however, the number of pregnancy complications has increased, and so has the demand for postpartum hemorrhage devices to treat patients and save the lives of mothers, assisting in the advancement of the industry.

Further, the increasing rate of complications in pregnancies is a major factor driving the demand for postpartum hemorrhage devices, thereby contributing to market growth. The 2021 bulletin published in the journal of Obstetrics and Gynecology explains the atrocities of anemia during pregnancy. Iron deficiency and abrupt blood loss are the two most common causes of anemia during pregnancy and puerperium. During pregnancy, iron requirements rise, and failing to maintain adequate iron levels can have negative maternal-fetal implications. Such factors will likely boost the adoption of postpartum hemorrhage devices, thereby contributing to market growth.

Moreover, market players are involved in marketing strategies like mergers and acquisitions of products launched. For instance, in 2021, Merck announced the acquisition of Alydia Health on behalf of its planned spinoff of Organon, which implements dedication to enhancing women's health through addressing unmet medical needs in maternal health by facilitating safer delivery. The Jada System, Alydia's technology, is designed to induce natural uterine contractions to prevent excessive bleeding after childbirth. The United States Food and Drug Administration granted Alydia 510(k) clearance (marketing authorization) for the Jada System in August 2020, based on the company's pivotal PEARLE IDE Study results. The Global Health Investment Fund and AXA IM Alts, through its Impact Investing Strategy, are Alydia's lead institutional investors. They are social impact funds that invest in innovative technologies that can generate attractive financial returns while helping address major public health issues worldwide. Additionally, in September 2021, Stryker announced the acquisition of Gauss Surgical, a medical device firm that created TritonTM, an artificial intelligence-powered platform for real-time blood loss monitoring during surgery. Triton has shown advantages in maternity and surgical care by detecting hemorrhage earlier and intervening sooner.

Furthermore, prominent market competitors favorably impact the industry's growth through new product releases and strategic efforts by prominent market competitors. For example, in March 2022 Baymatob's wearable devices completed capital rise to advance life-saving labor monitoring devices. Baymatob's wearable device Oli uses innovative sensor technology and AI interpretation to detect a Pending PPH during labor before postpartum bleeding starts.

Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period. However, the lack of trained professionals restrains the postpartum hemorrhage market growth.

Postpartum Hemorrhage Devices Market Trends

Uterine Tamponade Devices are Expected to Witness a Positive Growth Over the Forecast Period

Uterine balloon tamponade is a non-surgical treatment for refractory postpartum bleeding. It can be used to tamponade uterine bleeding without operational intervention once postpartum hemorrhage has been recognized, and medicinal care has been given. When filled with fluid, the collapsed balloon is put into the uterus, which adapts to the shape of the uterine cavity to tamponade uterine hemorrhage. The catheter's central lumen facilitates drainage and is meant to detect any bleeding that occurs above the balloon's level. By delivering tamponade to the bleeding, uterine surface, uterine packing is a safe, straightforward, and practical approach to controlling postpartum hemorrhage.

The study published in MDLinx in 2021 explains the future advances in vacuum-induced uterine tamponade devices, which impart negative pressure to the uterus, causing the bleeding cavity to contract and leaking blood vessels to close. This low-cost, noninvasive method could be precious in developing nations where other treatment options are limited. Hence, owing to the advantages offered by uterine balloon tamponade, the adoption of these products is likely to increase among the target population, ultimately driving the market growth.

Furthermore, in 2021, a research article published in BMJ Case Reports found that condom tamponade can significantly reduce maternal morbidity and mortality associated with postpartum hemorrhage. In that study, they explain that condom tamponade saves both time and life of patients with positive results.

As per the article published in 2021 in Pubmed Central, substantiating the use of Bakri balloon plus cervical cerclage for the prevention and treatment of postpartum hemorrhage in late pregnancy complicated with acute aortic dissection provides satisfactory results.

Therefore, the uterine tamponade segment is expected to witness significant positive growth over the forecast period due to the abovementioned factors.

North America is Expected to Dominate the Postpartum Hemorrhage Devices Market Over the Forecast Period

North America had the largest market share for postpartum hemorrhage devices during the forecast period. The emergence of this region can be attributed to an increase in postpartum bleeding or hemorrhage in the United States and the rest of North America. The article published in 2020 in The Commonwealth Fund publication, "Maternal Mortality and Maternity Care in the United States Compared to 10 Other Developed Countries," explains that the United States has the highest maternal mortality rate among developed countries. Approximately one-third of all pregnancy-related deaths in the United States occur during pregnancy, as measured up to one year after birth. Moreover, the Postpartum Hemorrhage market in North America is being driven by advancements in healthcare infrastructure and rising healthcare spending. Also, increased awareness of sophisticated postpartum hemorrhage treatments grows the market.

Furthermore, the other factors involved in the growth of the postpartum hemorrhage market include key product approvals, increased pregnancy complications, and mortality rate or manufacturer's presence in the country. For Instance, in September 2021, the Food and Drug Administration approved Jada System, a medical device designed to control and treat abnormal postpartum uterine bleeding or hemorrhage when conservative therapy is required. Jada was approved for the first time in August 2020, based on findings from the PEARLE IDE research (Identifier: NCT02883673), which found that the device was 94.3 percent effective (n=100/106; P.001) in preventing postpartum hemorrhage (primary endpoint; defined as the avoidance of nonsurgical, second-line or surgical intervention to control uterine bleeding after the use of the Jada System). As a result of the factors above, the studied market is expected to increase in the North American region.

Postpartum Hemorrhage Devices Market Competitor Analysis

The postpartum hemorrhage devices market is fragmented due to the presence of several companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold the market shares and are well known. Include Bactiguard, Cook Medical, Utah Medical Products, Inc., Teleflex Incorporated, and Organon & Co., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Occurrence of Conditions like Placental Abruption, Multiple Pregnancy and Inverted Uterus and other pregnancy complications (Anemia)
    • 4.2.2 Inflated Number of Government Initiatives Coupled with Increased Awareness
  • 4.3 Market Restraints
    • 4.3.1 High Cost of PPH Devices & Lack of Trained Proffesionals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Non-Pneumatic Anti-Shock Garment
    • 5.1.2 Prefilled Injection System
    • 5.1.3 Uterine Tamponade Devices
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Clinics
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bactiguard
    • 6.1.2 Cook Medical
    • 6.1.3 Utah Medical Products, Inc.
    • 6.1.4 Teleflex Incorporated
    • 6.1.5 Sinapi Biomedical
    • 6.1.6 Zoex Niasg
    • 6.1.7 3D Stone Design Inc.
    • 6.1.8 Organon & Co.
    • 6.1.9 Laborie (Clinical Innovations)
    • 6.1.10 Becton, Dickinson and Company
    • 6.1.11 Boen Healthcare Co., Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS